Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A
4(100.0%)
4Total
N/A(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT02536196Not ApplicableCompleted

The REFLECT Trial: Cerebral Protection to Reduce Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation

Role: lead

NCT01448421Not ApplicableCompleted

DEFLECT I: Keystone Heart Embolic Deflection Trial

Role: lead

NCT02073851Not ApplicableCompleted

DEFLECT II: A Study to Evaluate the Safety and Performance of the TriGuard™HDH in Patients Undergoing TAVR

Role: lead

NCT02073864Completed

A Study to Evaluate the Neuro-embolic Consequences of TAVR

Role: lead

NCT02070731Not ApplicableCompleted

DEFLECT III: A Prospective, Randomized Evaluation of the TriGuard™ HDH Embolic Deflection Device During TAVI

Role: lead

All 5 trials loaded